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Summary.-The serum of athymic nude mice bearing rat tumour xenografts has been examined fortumour-specific antigen. With asarcomaand ahepatoma,tumour-
specific antigen expression continued in xenograft growths, and sera of tumour-
bearing mice contained free antigen, assayed by its ability to neutralise reactivity of tumour-immune rat sera against tumour target cells in an indirect membrane-
immunofluorescence test. In contrast, no anti-rat antibody was detectable in sera of
mice bearing the xenografts, or rejecting cells injected in admixture with BCG.
IMMUNOSUPPRESSED and congenitally
athymic (nude) mice are becoming widely
used to study the growth of malignant
xenografts, particularly human tumours,
and to assess their responses to chemo-
therapy (Houghton et al., 1977; Povlsen
& Jacobsen, 1975; Kopper & Steel,
1975; Lamerton & Steel, 1975; Sonis et
al., 1977), radiotherapy (Davy et al., 1977)
and immunotherapy (Pimm & Baldwin,
1978) and to examine their growth kinetics
(Pickard et al., 1975; Houghton & Taylor,
1978a; Lamerton & Steel, 1975), karyo-
types (Reeves & Houghton, 1978) and
metabolism (Houghton & Taylor, 1978b).
It is clearly important to establish that
tumours growing as xenografts retain
fundamental characteristics expressed in
the primary donor or, in the case ofexperi-
mental tumours, on syngeneic transplanta-
tion. In this context, human tumour xeno-
grafts have been shown to continue the
production of several tumour-associated
materials. For example, xenografts of
Burkitt's lymphoma produce IgM (Povlsen
et al., 1973) colon carcinomas produce
CEA (Mach et al., 1974; Houghton &
Taylor, 1978b), and breast carcinoma pro-
duces calcitonin (Coombes et al., 1975). In
the light ofthese observations with human
xenografts, the present work was carried
out to examine xenografts ofexperimental
rat tumours for the continued production
of their characteristic tumour-associated
antigens, and to examine sera of tumour-
bearing mice for free circulating tumour-
specific antigen, as an experimental basis
for the examination of human-xenograft
bearers for tumour-specific products. The
rat tumours used, a carcinogen-induced
sarcoma and hepatoma, have unique cell-
surface neo-antigens demonstrable in
vitro by indirect membrane-immunofluo-
rescence reactions with tumour-immune
rat sera. The expression of these antigens
on cells of xenograft growths has been
assessed, and sera of tumour-bearing mice
examined for free antigen by their ability
to neutralize the reactivity of tumour-
immune rat serum. The development of
anti-rat antibody in xenograft bearers and
in mice rejecting tumour cells injected in
admixture with BCG has also been exam-
ined.
MATERIALS AND METHODS
Athymic mice.-Athymic nude (CBA nu/nu
or ONU nu/nu) mice and heterozygous (CBA
nu/+) mice were purchased from the Medical
Research Council Laboratory Animal Centre,
Carshalton, Surrey. They were fed standard
laboratory diet (Oxoid) and tap water adRAT TUMOURS IN NUDE MICE
libitumn while housed in plastic cages with saw-
dust bedding held in Filter Rack Ventilation
Cabinets (Anglia Laboratory Animals, Alcon-
bury, Huntingdon, Cambridge).
Tuinours. The rat tumours used were in-
duced in adult rats of a Wistar-derived.
Nottingham Inbred Strain (WAB/Not) by
carcinogen administration. Sarcoma Mc7 wras
induced by s.c. injection of 3-methylcholan-
threne (Baldwin & Pimm, 1971) and hepa-
toma D23 by oral administration of 4-
dimethylaminoazobenzene (Baldwin &
Barker, 1967a). These tumours have been
maintained by routine s.c. trocar grafts in
syngeneicrecipients. Both possessindividually
distinct neoantigens, demonstrable by in vivo
transplant-rejection reactions and in vitro
by indirect membrane-immunofluorescence
reactions with syngeneic tumour-immune rat
sera (Baldwin & Pimm, 1971; Baldwin &
Barker 1967a, b).
For the present studies, in vitro culture
lines were established in Eagle's medium
supplemented with 10% calf serum and
routinely harvested in 0-2500 trypsin, washed
and suspended in Hanks' Solution.
Growth of xenografts.-Tumour growths
wvere initiated by subcutaneous injection in
the right flank of cells harvested from tissue
culture. In some cases mice received one or
two injections of cells in direct admixture
with 500 tg moist weight of BCG organisms
(Glaxo Percutaneous Vaccine, B.P., Glaxo
Laboratories, Greenford, Middlesex); these
inocula wvere consistently rejected (Pimm &
Baldwin, 1975). Mice were bled by cardiac
puncture under ether anaesthesia, blood
clotted at room temperature and stored at
+4°C for 18 h. Cellular contamination was
removed from serum by centrifugation at 500
g for 15 min, and serum clarified bycentrifuga-
tion at 1500 g for 30 min and stored at-20°C.
Preparation of antisera.-Hepatoma D23
and sarcoma Mc7-specific antisera -were
raised in syngeneic WAB/Not rats by re-
peated s.c. implantation of 60Co y-irradiated
(15,000 rad) tumour tissue (Baldwin &
Barker, 1967b).
Allogeneic, anti-WAB/Not sera was raised
in KX/Not rats by repeated implantation of
viable D23 tumour tissue, these grafts being
consistently rejected.
Mouse anti-rat serum was raised in hetero-
zygous CBA nu/+ mice by i.p. injections of
viable rat sarcoma Mc7 cells, these being
consistently rejected.
Assayfor antibody.-Rat tumour cells were
harvested from tissue culture or prepared by
trypsin digestion of solid xenograft growths
from athymic mice (Baldwin & Barker,
1967b). 2 x 106-5 x 106 cells were incubated
for 20 min at room temperature w%Aith 0-1 ml
serum, washed x4 in Hanks' solution and
resuspended in 01 ml of fluorescein-labelled
antiglobulin, incubated for a further 20 min,
washed x 4 in Hanks' solution and finally
suspended in 1:1 (v/v) glycerol:phosphate-
buffered saline (pH 7.2). For tests wAith rat
antisera, normal rat serum was used as a
negative control, and the fluorescent anti-
serum was rabbit anti-rat IgG, prepared in
this laboratory; tests with mouse sera had
normal mouse serum (nu/nu or nu/+l) as
negative control, and fluorescein-labelled goat
anti-mouse globulin (Nordic Diagnostics,
London, diluted 1/30). Cells were examined
with a Reichert Zetopan fluorescence micro-
scope (x 600) and cells showing complete or
partial membrane fluorescence scored as
positively stained. A fluorescence index (FI)
wAas calulated for each serum as:
Fl-
00 cells unstained by control sera-
00 cells unstained by test serum
00 cells unstained by control serum
Assay for serum antigen.-Rat tumour-
specific antiserum wias incubated with serum
from mice bearing rat tumour xenografts for
30 min at room temperature, at a ratio of 0-1
ml antisera:0'02-0-2 mltumour-bearer serum.
The incubated mixture was assayed for free
antibody as outlined above by immunofluo-
reseence reaction against appropriate target
cells. Untreated serum and serum mixed with
normal mouse serum A-ere included as controls
in the tests.
RESULTS
Tumour-specific antigen expression on
xenograft growths
To confirm that serologically defined
tumour-specific antigens, known to be
expressed on cells of sarcoma Mc7 and
hepatoma D23 in syngeneic transplants,
were similarly expressed in xenografts in
athymic mice, indirect membrane immu-
nofluorescence(MIF)reactionswere carried
out with rat tumour-immune sera and
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TABLE I.-Demonstration oftumour-specific
antigens on rat tumour cells
Immunofluorescence index (FI) against
target cells
Hepatoma D23 Sarcoma Mc7
from from
Rat .-
antiserum Tissue Tissue
against culture Xenograft culture Xenograft
Hepatoma0-61, 0-69 0 30, 0 39 0 00, 0-15 0 00, 0 00
D23 0-46, 0 59 0-14
Sarcoma 0 00 0 00, 0-02 0-56, 0-72 0-48, 0 54
Mc7 0 59, 0 59
KXAnti- 1 00 0 95, 0 99 1 00 0-69, 0-92
WAB/Not 0-89, 1-00 1.00,1 00
cells prepared from xenograft growths
(Table I). Rat tumour-immune sera re-
acted specifically with tissue-culture lines
of Mc7 and D23, and with cells from their
xenografts. For example, D23 immune
serum gave FJs of 0-61-0-69 against the
tissue-cultured line of D23, but insignifi-
cant reactions against Mc7 cultured cells
(Fl 000-0-15). This serum also reacted
with cells of all 4 D23 xenograft growths
examined (Fl 0-30-0.59), but not with cells
from Mc7 xenografts.
The allogeneic antiserum against WAB/
Not tissue, raised in KX rats, reacted
strongly with cells of both Mc7 and D23.
In some cases, however, reactivity against
cells prepared from xenografts was not as
complete as that with culture-derived
cells, as shown by FIs less than 1-00. This
may reflect contamination ofthe xenograft
preparation with mouse stromal or blood-
vessel cells, although no attempt was made
to actively demonstrate these host cells,
and indeed the technique of cell prepara-
tion and handling (Baldwin & Barker,
1967b) may not be suitable for their
recovery.
Anti-rat antibody in xenograft bearers and
in mice rejecting cells after BCG treatment
Sera from groups of mice bearing xeno-
grafts ofD23 and Mc7 were tested for anti-
rat antibody by MIF reactions against D23
and Mc7 target cells (Table II). In no case
was a significant reaction detected, using
sera from mice with 24-46-day-oldgrowths
TABLE II.-Immunofit orescence tests with
sera ofmice bearing rat tumour xenografts
against rat tumour cells
Tumour of serum-donor mice*
No. Mean FL vns cells of
cells (lia- ._
in- Age meter Sarcoma Hepatoma
Type jected (days) (cm) Mc7 D23
Sarcoma 106 24 1-3 0 00 0 03
Mc7 28 1.5 0 01 0 00
46 1l5 000 0.01
24 1-6 0-02 0.00
24 1-7 000 000
Hepatoma 105 27 1-2 0-01 0-02
D23 32 1-5 0-00 0-00
35 1-0 0-01 0-01
Heterozygous (ntu/+) anti-rat 1-00, 1-00 0-98, 0-99
* Sera pooled from 1-4 mice.
up to 1P7 cm in diameter. In contrast, sera
from heterozygous mice rejecting rat sar-
coma Mc7 cells reacted strongly with both
Mc7 and D23 target cells (Fl 0-98-1-00).
G-roups of athymic mice were injected
s.c. with cells of Mc7 or D23 in admixture
with BCG. These inocula failed to grow
out, in keeping with previous observations
(Pimm & Baldwin, 1975) and the mice
were subsequently tested for anti-rat anti-
body by the MIF reaction. Some mice re-
ceived 2 injections ofcells and BCG, at 30-
day inter-vals. The sera from none of these
groups ofmice had antibody detectable by
the MIF reaction (Table III) but again
sera from heterozygous mice, rejecting
tumour cells alone, reacted strongly.
TABLE III. Immunofluorescence tests with
sera ofathymic mice rejecting rqt tumour
cells injected in admixture with BCG
Inoculum rejected* Fl V-s cells of
No. BCG Sarcoma Hepatoma
Tumour cells (t,g) Mc7 D23
Mc7 106 500 0-00 0-02
D23 105 500 0-07 0-00
D23 ft1o' 500 0-00 0-01
IO.~ 500
D23 < 105 500 0-00 0-01
D2 105 300
Heterozygous (nu/l) ainti iat 1-00 0-99
* Sertum pooled from 1-3 mice.
t 2 injections at contralateral s.c. sites at 30-day
intervals.
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Detection of tumour-specific antigen in the
serum of xenograft-bearing mice
The sera of athymic mice bearing xeno-
grafts were assayed for antigen by their
ability to neutralize the reaction of rat
tumour-immuine antisera against appro-
priate target cells in the MIF test. The
results of these assays (Table IV) showed
TABLE IV.-Neutralization of rcat tumour-
immnnune serum by serum of athymic mice
bearing tumour xenografts
Tuimour of serum-donor
mice*
r_ _A_ A_
NrO. Mean
cells dia-
in- Age meter
Type jecte(1 (days) (cm)
AIc7 106 46 1.5
24
28
22
23
40
26
1-7
1-4
1*1
1 3
2-0
1-2
* Sera pooledC from 1-4 mice.
t 0-1 ml mouse serum a(d(le(l to
iilmmune i-at' serum.
Immunofluorescence
in(lex of tumour-
immune rat sera
admixed witht
Ttumouir-
bearer Normal
mouse mouse
- serum serum
0 59 0-25
0-55 0-14
0-18 0 59
0-56 0-00 0.55
0-44 0-01
0-65 0-11
0-56 0-05
0-85 0-09
0-72 000 0663
0-59 0-45
0-59 0-47
0-44 0-00
0-67 0-00
0-1 ml tuimotur-
0.8
0.7
- 0.6-
0.5-
VI 0. 5 -
c
x
-C 0.43
CD
L-
0.05 0.10 0.15 0.20 0.25
ml tumour bearer serum/0. ml antiserum
FIGURE. Neutralization of Mc7 tumour-
specific antiserum by sera of athymic mice
bearing Mc7 xenografts. 0-1 ml aliquots of
rat Mc7 tumour-specific antiserum were
incubated with increasing volumes of
serum from 3 mice bearing rat sarcoma
Mc7 xenografts for 30 min at room tem-
perature, and subsequently assayed for
remaining free antibody by the indirect
immunofluorescence test, against sarcoma
Mc7 cells.
that 4/5 pools of sera from mice with Mc7
xenografts contained antigen, and both of
2 serum pools from D23 bearers were also
positive. For example, in the first test,
sera from mice with 46-day-old xenografts
of Mc7 reduced the FI of Mc7 antiserum
from 0-55-0-59 to 0-14-0-25, when 0-1 ml
tumour-bearer serum was mixed with 0-1
ml antiserum, while normal mouse serum
(nit/nu) had no neutralizing effect (FI of
mixture, 0.59). The 2 D23 tumour-bearer
sera reduced the Fl of D23-immune serum
from 0-44-0-67 to zero. A cross test carried
out with the second of these D23 tumour-
bearer sera showed that this neutralization
of antiserum was specific, the D23-bearer
seruim failing to neutralize the reactivity
of Mc7 antiserum against Mc7 target cells
in 2 separate tests (FIs of untreated
serum: 0-55, 0-72; FJ after mixture with
D23 bearer serum: 0-56, 0.63).
To determine the amount of tumour-
bearer mouse serum required to neutralize
a standard volume of tumour-immune
serum, tests were carried out with 0-02-
0-25 ml Mc7 xenograft bearer serum mixed
with 0-1 ml rat tumour-immune serum
(Fig.). With 3 individual tumour-bearer
sera, increasing amounts of serum pro-
MC7 106
fc7 106
Mc7 106
M\c7 106
D23 105
D23 1(i
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duced progressive neutralization of re-
activity.
DISCUSSION
Human tumours growing as xenografts
in congenitally athymic or immunosup-
pressed mice have been reported to con-
tinue the production of characteristic
tumour-associated secretory products.
Thus, a xenograft of Burkitt's lymphoma
continued the production of IgM (Povlsen
et al., 1973), human colon-tumour xeno-
grafts produce characteristic epithelial
mucin (Houghton & Taylor, 1978b) CEA
and AFP, these latter demonstrable both
within the xenograft and free in the host
serum (Mach et al., 1974; Houghton &
Taylor, 1978b; Miwa et al., 1977). Simi-
larly, a choriocarcinoma synthesized HCG
(Kamneya et al., 1976), and human mam-
mary carcinomas continue to produce cal-
citonin (Coombes et al., 1975) and tumour-
associated glycolipid (absent from non-
malignant tissue) and shed this into the
serum (Nordquist et al., 1978). Similar
studies with animal-tumour xenografts
have demonstrated the synthesis of mye-
loma protein by a mouse plasmacytoma,
insulin by a hamster pancreatic-islet-cell
tumour, and SV40 T-antigen by SV40-
transformed mouse, rat and rabbit cells
(Freedman et al., 1976). The objective of
the present studies was to examine the
continued production in xenografts of the
unique cell-surface tumour-associated neo-
antigens of 2 carcinogen-induced rat tu-
mours, and here it has been demonstrated
that these antigens are expressed during
xenograft growth. Moreover, free antigen,
assayed by its ability tospecificallyneutra-
lize tumour-specific antibody, was demon-
strable in the serum of xenograft bearers.
Antigen is similarly shed during growth
of these tumours in syngeneic rats, but is
then frequently complexed with tumour-
specific antibody (Bowen & Baldwin,
1976; reviewed by Price & Baldwin,
1977). Assays carried out in the present
study were with sera of mice with large
tumours (1-2 cm in diameter) and no
attempt has yet been made to correlate
the level of serum tumour antigen and
tumour size. It is probable that the serum
of tumour-bearing mice contains other rat
tumour products in addition to tumour-
specific antigen, including species-specific
antigens, but assays for these have not
been carried out.
The present tests were unable to detect
antibody to tumour-specific antigens or
rat species antigens in the serum of mice
developing xenografts. These findings do
not exclude the possibility of the presence
in tumour-bearer serum of antibody-
antigen complexes in antigen excess, al-
though mice rejecting 2 inocula of tumour
cells prevented from growth by the local
application ofBCG, also had no detectable
antibody. With virally induced tumours,
athymic mice bearing growths of SV40-
induced tumours similarly fail to develop
antibody to SV40 T antigen, assayed by
irnmunofluorescence reactions, or virus
neutralizing antibody (Tevethia et al.,
1977) although inoculation of polyoma
virus evokes antibody to virus, detectable
byhaemagglutination inhibition (Stutman,
1975). With human tumour xenografts,
anti-human antibody was demonstrable
in the serum of athymic mice with a
Burkitt's lymphoma xenograft (Povlsen
et al., 1973) by both an indirect membrane-
immunofluorescence test similar to that
used here, and by complement-dependent
cytotoxicity. However, antibody against
membrane-associated EBV virus was not
demonstrable, and the precise antigenic
components of the human cells in the
athymic mice were unresolved. Similar
studies with mice bearing xenografts ofthe
human bladder carcinoma lineT24failedto
detectantibodybythemembrane-immuno-
fluorescence test (Pimm & Baldwin, 1978).
Essentially the present studies extend
those of others who have demonstrated
continued production or excretion of
tumour-associated materials, showing that
individually distinct tumour-specific com-
ponents are also produced during xeno-
graft growth. Taken as a whole, these
studies indicate that many fundamental
characteristics of malignant cells remain
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unchanged during xenograft development,
strengthening the case that xenografts
may be used as models for the assessment
of therapeutic protocols and as a source
of tumour tissue or antigen, and that the
serum of tumour-bearing animals may be
a suitable source of tumour products.
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